-
公开(公告)号:US5595990A
公开(公告)日:1997-01-21
申请号:US411240
申请日:1995-03-27
申请人: John J. Baldwin , David A. Claremon , Jason M. Elliott , Nigel Liverton , David C. Remy , Harold G. Selnick
发明人: John J. Baldwin , David A. Claremon , Jason M. Elliott , Nigel Liverton , David C. Remy , Harold G. Selnick
IPC分类号: A61K31/5513 , A61K31/55 , A61K31/551 , A61K38/00 , A61P9/00 , A61P9/06 , C07D243/14 , C07D243/24 , C07D401/04 , C07D401/12 , C07D403/12 , C07D405/04 , C07D405/12 , C07D409/12 , C07D413/10 , C07D413/12 , C07D471/04 , C07D487/04 , C07D495/04 , C07K5/06 , C07K5/078 , A61K31/38
CPC分类号: C07D401/04 , A61K31/55 , C07D243/14 , C07D243/24 , C07D401/12 , C07D403/12 , C07D405/04 , C07D405/12 , C07D409/12 , C07D413/10 , C07D413/12 , C07D471/04 , C07D487/04 , C07D495/04 , C07K5/06026 , C07K5/06139 , A61K38/00 , Y10S514/821
摘要: Benzo-(1,5)-diazepine derivatives with an amide or urea function in the 3-position are useful in the treatment of arrhythmia. The compounds have structural formulae: ##STR1##
摘要翻译: 具有3-位氨基或脲官能团的苯并(1,5) - 二氮杂衍生物可用于治疗心律失常。 化合物具有结构式:
-
公开(公告)号:US5451578A
公开(公告)日:1995-09-19
申请号:US289974
申请日:1994-08-12
IPC分类号: C07D221/20 , C07D471/10 , A61K31/55
CPC分类号: C07D221/20 , C07D471/10
摘要: Compounds of the invention have the formula: ##STR1## which have fibrinogen receptor antagonist activity, including, for example, ##STR2##
摘要翻译: 本发明的化合物具有下式:具有纤维蛋白原受体拮抗剂活性的
,包括例如 -
公开(公告)号:US5438055A
公开(公告)日:1995-08-01
申请号:US156183
申请日:1993-11-22
申请人: John J. Baldwin , Jason M. Elliott , David A. Claremon , Nigel Liverton , David C. Remy , Harold G. Selnick
发明人: John J. Baldwin , Jason M. Elliott , David A. Claremon , Nigel Liverton , David C. Remy , Harold G. Selnick
IPC分类号: A61K31/55 , A61K31/551 , A61K45/06 , A61P9/06 , A61P9/08 , A61P9/10 , C07D243/14 , C07D403/04
CPC分类号: C07D403/04 , A61K31/55 , A61K45/06 , C07D243/14 , Y10S514/821
摘要: Benzodiazepine derivatives with an amide or urea function in the 3-position are useful in the treatment of arrhythmia. The compounds have structural formulae: ##STR1##
摘要翻译: 在3-位具有酰胺或脲官能团的苯并二氮杂衍生物可用于治疗心律失常。 该化合物具有结构式:
-
公开(公告)号:US06495561B2
公开(公告)日:2002-12-17
申请号:US09861861
申请日:2001-05-21
IPC分类号: C07D47106
CPC分类号: C07D403/12 , C07D235/08 , C07D235/10 , C07D235/12 , C07D235/14 , C07D235/16 , C07D235/30 , C07D405/12 , C07D417/12
摘要: 4-substituted cyclohexanes substituted in the 1-position with imidazopyridine either directly or through a C1-C4alkyl, C1-C4alkenyl, C1-C4alkynyl, C1-C4alkoxy, amino, aminoC1-C4alkyl, hydroxyC1-C4alkyl, carbonyl, cycloC3-C6alkyl or aminocarbonyl chain are effective as NMDA NR2B antagonists useful for relieving pain.
摘要翻译: 通过直接或通过C 1 -C 4烷基,C 1 -C 4链烯基,C 1 -C 4炔基,C 1 -C 4烷氧基,氨基,氨基C 1 -C 4烷基,羟基C 1 -C 4烷基,羰基,环C 3 -C 6烷基或氨基羰基取代在1-位上与咪唑并吡啶取代的4-取代的环己烷 链可用作缓解疼痛的NMDA NR2B拮抗剂。
-
公开(公告)号:US20140200223A1
公开(公告)日:2014-07-17
申请号:US14132877
申请日:2013-12-18
申请人: Salvacion Cacatian , David A. Claremon , Lawrence Wayne Dillard , Klaus Fuchs , Niklas Heine , Lanqi Jia , Katerina Leftheris , Brian Mckeever , Angel Morales-Ramos , Suresh B. Singh , Shankar Venkatraman , Guosheng Wu , Zhongren Wu , Zhenrong Xu , Jing Yuan , Yajun Zheng
发明人: Salvacion Cacatian , David A. Claremon , Lawrence Wayne Dillard , Klaus Fuchs , Niklas Heine , Lanqi Jia , Katerina Leftheris , Brian Mckeever , Angel Morales-Ramos , Suresh B. Singh , Shankar Venkatraman , Guosheng Wu , Zhongren Wu , Zhenrong Xu , Jing Yuan , Yajun Zheng
IPC分类号: C07D271/12 , C07D239/70 , C07D403/06 , C07D498/10 , C07D417/06 , C07D405/06 , C07D413/04 , C07D233/46
CPC分类号: C07D271/12 , C07D233/46 , C07D235/02 , C07D239/70 , C07D277/60 , C07D279/08 , C07D401/04 , C07D401/06 , C07D403/04 , C07D403/06 , C07D405/06 , C07D405/12 , C07D405/14 , C07D409/04 , C07D413/04 , C07D413/06 , C07D417/04 , C07D417/06 , C07D417/10 , C07D487/10 , C07D491/10 , C07D493/20 , C07D495/10 , C07D498/10 , C07D513/10
摘要: The present invention is directed to a compound represented by the following structural formula or a pharmaceutically acceptable salt thereof. Pharmaceutical compositions and method of use of the compounds are also described.
摘要翻译: 本发明涉及由以下结构式表示的化合物或其药学上可接受的盐。 还描述了化合物的药物组合物和使用方法。
-
公开(公告)号:US08673899B2
公开(公告)日:2014-03-18
申请号:US13347784
申请日:2012-01-11
申请人: David A. Claremon , Linghang Zhuang , Katerina Leftheris , Colin M. Tice , Zhenrong Xu , Yuanjie Ye , Suresh B. Singh , Salvacion Cacatian , Wei Zhao
发明人: David A. Claremon , Linghang Zhuang , Katerina Leftheris , Colin M. Tice , Zhenrong Xu , Yuanjie Ye , Suresh B. Singh , Salvacion Cacatian , Wei Zhao
IPC分类号: C07D413/10 , C07D413/14 , A61K31/5355
CPC分类号: C07D413/10 , C07D413/14
摘要: This invention relates to novel compounds of the Formula Ik, Im1, Im2, Im5, In1, In2, In5, Io1, Io2, Io5, Ip1, Ip3, pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof, which are useful for the therapeutic treatment of diseases associated with the modulation or inhibition of 11β-HSD1 in mammals. The invention further relates to pharmaceutical compositions of the novel compounds and methods for their use in the reduction or control of the production of cortisol in a cell or the inhibition of the conversion of cortisone to cortisol in a cell.
摘要翻译: 本发明涉及可用于治疗性治疗的式Ik,Im1,Im2,Im5,In1,In2,In5,Io1,Io2,Io5,Ip1,Ip3,其药学上可接受的盐及其药物组合物的新型化合物 的与哺乳动物中的11beta-HSD1的调节或抑制相关的疾病。 本发明进一步涉及新化合物的药物组合物及其用于减少或控制细胞中皮质醇产生或抑制细胞中可的松转化为皮质醇的方法。
-
公开(公告)号:US08633212B2
公开(公告)日:2014-01-21
申请号:US12723137
申请日:2010-03-12
申请人: Salvacion Cacatian , David A. Claremon , Lawrence W. Dillard , Klaus Fuchs , Niklas Heine , Lanqi Jia , Katerina Leftheris , Brian McKeever , Angel Morales-Ramos , Suresh B. Singh , Shankar Venkatraman , Guosheng Wu , Zhongren Wu , Zhenrong Xu , Jing Yuan , Yajun Zheng
发明人: Salvacion Cacatian , David A. Claremon , Lawrence W. Dillard , Klaus Fuchs , Niklas Heine , Lanqi Jia , Katerina Leftheris , Brian McKeever , Angel Morales-Ramos , Suresh B. Singh , Shankar Venkatraman , Guosheng Wu , Zhongren Wu , Zhenrong Xu , Jing Yuan , Yajun Zheng
IPC分类号: A61K31/405 , A61K31/415 , A61K31/41 , A61K31/40 , C07D237/00 , C07D271/10 , C07D487/10 , C07D209/54
CPC分类号: C07D271/12 , C07D233/46 , C07D235/02 , C07D239/70 , C07D277/60 , C07D279/08 , C07D401/04 , C07D401/06 , C07D403/04 , C07D403/06 , C07D405/06 , C07D405/12 , C07D405/14 , C07D409/04 , C07D413/04 , C07D413/06 , C07D417/04 , C07D417/06 , C07D417/10 , C07D487/10 , C07D491/10 , C07D493/20 , C07D495/10 , C07D498/10 , C07D513/10
摘要: The present invention is directed to a compound represented by the following structural formula or a pharmaceutically acceptable salt thereof. Pharmaceutical compositions and method of use of the compounds are also described.
摘要翻译: 本发明涉及由以下结构式表示的化合物或其药学上可接受的盐。 还描述了化合物的药物组合物和使用方法。
-
公开(公告)号:US08569292B2
公开(公告)日:2013-10-29
申请号:US12990306
申请日:2009-04-30
申请人: David A. Claremon , Linghang Zhuang , Katerina Leftheris , Colin M. Tice , Zhenrong Xu , Yuanjie Ye , Suresh B. Singh , Salvacion Cacatian , Frank Himmelsbach , Matthias Eckhardt , Wei Zhao
发明人: David A. Claremon , Linghang Zhuang , Katerina Leftheris , Colin M. Tice , Zhenrong Xu , Yuanjie Ye , Suresh B. Singh , Salvacion Cacatian , Frank Himmelsbach , Matthias Eckhardt , Wei Zhao
IPC分类号: C07D413/10 , C07D413/14 , A61K31/5355
CPC分类号: C07D413/10 , C07D413/14 , C07D417/10 , C07D417/14
摘要: This invention relates to novel compounds of the Formula I, Ik, Iq1-21, Ir1-21, Is1-21, It1-7, pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof, which are useful for the therapeutic treatment of diseases associated with the modulation or inhibition of 11 β-HSD1 in mammals. The invention further relates to pharmaceutical compositions of the novel compounds and methods for their use in the reduction or control of the production of cortisol in a cell or the inhibition of the conversion of cortisone to cortisol in a cell.
摘要翻译: 本发明涉及式I,Ik,Iq1-21,Ir1-21,Is1-21,It1-7,其药学上可接受的盐及其药物组合物的新型化合物,其可用于治疗与 哺乳动物中11β-HSD1的调节或抑制。 本发明进一步涉及新化合物的药物组合物及其用于减少或控制细胞中皮质醇产生或抑制细胞中可的松转化为皮质醇的方法。
-
公开(公告)号:US08455521B2
公开(公告)日:2013-06-04
申请号:US12802142
申请日:2010-05-28
申请人: John J. Baldwin , David A. Claremon , Colin M. Tice , Salvacion Cacatian , Lawrence W. Dillard , Alexey V. Ishchenko , Jing Yuan , Zhenrong Xu , Gerard McGeehan , Wei Zhao , Robert D. Simpson , Suresh B. Singh , Patrick T. Flaherty , Jean-Pierre Wery
发明人: John J. Baldwin , David A. Claremon , Colin M. Tice , Salvacion Cacatian , Lawrence W. Dillard , Alexey V. Ishchenko , Jing Yuan , Zhenrong Xu , Gerard McGeehan , Wei Zhao , Robert D. Simpson , Suresh B. Singh , Patrick T. Flaherty , Jean-Pierre Wery
IPC分类号: C07D417/04 , C07D409/06 , C07D405/06 , C07D401/06 , C07D417/06 , C07D265/30 , C07D211/22 , C07D211/26 , A61K31/5377 , A61K31/5375 , A61K31/445 , A61K31/4525 , A61K31/453 , A61K31/4535 , A61K31/454 , A61K31/4545
CPC分类号: C07D417/06 , C07C233/40 , C07C235/40 , C07C235/42 , C07C271/20 , C07C2601/08 , C07C2601/14 , C07C2603/74 , C07D211/22 , C07D211/56 , C07D401/06 , C07D405/06 , C07D405/12 , C07D409/06 , C07F7/081 , C07F7/0812
摘要: Diaminoalkanes of below Formula I have now been found which are orally active and bind to aspartic proteases to inhibit their activity: They are useful in the treatment or amelioration of diseases associated with elevated levels of aspartic protease activity. The invention also relates to a method for the use of the compounds of Formula I in ameliorating or treating aspartic protease related disorders in a subject in need thereof comprising administering to said subject an effective amount of a compound of Formula I.
摘要翻译: 现已发现以下式I的二氨基烷烃是口服活性的并与天冬氨酸蛋白酶结合以抑制其活性:它们可用于治疗或改善与升高的天冬氨酸蛋白酶活性水平相关的疾病。 本发明还涉及在有需要的受试者中使用式I化合物来改善或治疗天冬氨酸蛋白酶相关病症的方法,包括向所述受试者施用有效量的式I化合物。
-
公开(公告)号:US20130096108A1
公开(公告)日:2013-04-18
申请号:US13646031
申请日:2012-10-05
申请人: Frank Himmelsbach , David A. Claremon , Linghang Zhuang , Katerina Leftheris , Zhenrong Xu , Colin M. Tice
发明人: Frank Himmelsbach , David A. Claremon , Linghang Zhuang , Katerina Leftheris , Zhenrong Xu , Colin M. Tice
IPC分类号: C07D413/10 , C07D413/14
CPC分类号: C07D413/10 , C07D413/14
摘要: Disclosed is a compound represented by Formula (Im1): or a pharmaceutically acceptable salt, monohydrate, enantiomer or diastereomer thereof. Also disclosed are pharmaceutical compositions comprising the compound of Formula (Im1) or a pharmaceutically acceptable salt, monohydrate, enantiomer or diastereomer thereof and methods of inhibiting 11β-HSD1 activity comprising the step of administering to a mammal in need of such treatment an effective amount of a compound of Formula (Im1), or a pharmaceutically acceptable salt, monohydrate, enantiomer or diastereomer thereof. Values for the variables in Formula (Im1) are defined herein.
摘要翻译: 公开了由式(Im1)表示的化合物或其药学上可接受的盐,一水合物,对映体或非对映体。 还公开了包含式(Im1)化合物或其药学上可接受的盐,一水合物,对映异构体或非对映体的药物组合物和抑制11beta-HSD1活性的方法,其包括向需要这种治疗的哺乳动物施用有效量的 式(Im1)的化合物或其药学上可接受的盐,一水合物,对映体或非对映异构体。 公式(Im1)中变量的值在此定义。
-
-
-
-
-
-
-
-
-